Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Nyxoah S.A.NASDAQ: NYXH

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of €1.98M rose 446.2% year over year, ahead of the +149.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 32.5% from the prior quarter. Over 3 fiscal years it compounded at +32.4% a year.

Context

  • Depreciation & amortization amounted to 44.8% of revenue in FY2025, up 27.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +446.2% holds above the trailing-twelve-month pace of +149.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.98M+32.5% QoQ
Last fiscal yearDec 2025
€4.48M+486.9% YoY
LTMMar 2026
€5.27M+149.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+446.2%——
1 year+486.9%——
3-year CAGR+32.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the income statement

Latest · FY2025
4.48M EUR
Year-over-year change
+486.9%
4-year CAGR
+28.2%

Depreciation & Amortization vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +149.9% is the highest of 10, against a peer median of +11.1%.
  • Depreciation & amortization amounts to 32.3% of revenue for NYXH, versus a peer median of 5.6%.
NYXH Competitors
Depreciation & Amortization for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$23.01M USD-1.6%+6.0%79.6%
OSUROraSure Technologies, Inc.LTM Mar 2026$9.54M USD+11.9%-10.7%8.4%
NYXHNyxoah S.A.LTM Mar 2026€5.27M EUR+149.9%+32.4%32.3%
PREPrenetics Global LimitedLTM Mar 2026$3.97M USD+79.9%-20.6%3.5%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$3.65M USD+35.4%+111.4%589.8%
STIMNeuronetics, Inc.LTM Mar 2026$3.3M USD+36.1%+28.1%2.2%
UTMDUtah Medical Products, Inc.LTM Mar 2026$2.93M USD+2.1%-25.3%7.8%
IVVDInvivyd, Inc.LTM Mar 2026$1.88M USD-43.4%+65.8%3.4%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$790.67K USD+4.2%+11.3%1.8%
TARAProtara Therapeutics, Inc.LTM Mar 2026$369K USD+11.1%+13.4%—
Peer median (excluding NYXH) —+11.1%+11.3%5.6%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.